QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

DISEASE CHARACTERISTICS: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of pancreatic cancer. * For dose escalation phase (Phase Ib) distant metastatic disease or unresectable disease and not a candidate for down staging to resection. * For expansion phase (Phase II) distant metastatic disease only. * For dose escalation phase (Phase Ib) 0 or 1 prior lines of chemotherapy for advanced pancreatic cancer. Prior gemcitabine is allowed, however prior nab-paclitaxel is not allowed. * For expansion phase (Phase II) no prior therapy for pancreatic cancer is allowed except for adjuvant therapy as long as it was completed ≥ 6 months prior to study treatment start * Have at least one untreated and progressing tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor * Prior radiation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Radiation therapy must have been completed at least 4 weeks prior to the baseline scan * Resolved acute effects of any prior therapy to baseline or Grade ≤1 * The Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2 * Life expectancy ≥12 weeks * Glomerular Filtration Rate (GFR) \> 40mL (milliliter)/min; Creatinine ≤ 1.5 x ULN (Upper limit of Normal) * Platelets ≥100,000/uL (microliter) * Hemoglobin ≥ 9g/dL * Absolute Lymphocytes ≥800/uL * Absolute neutrophil count/absolute granulocyte count ≥1500/uL * Total bilirubin ≤ 2.0 X ULN, or ≤ 3.0 X ULN (for patients with Gilbert's Syndrome) * aspartate aminotransferase, alanine aminotransferase ≤ 2.5 X ULN, or ≤ 5.0 X ULN (if liver metastasis present) * Normal clinical assessment of pulmonary function * Negative serum pregnancy test if female and of childbearing potential * Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study * Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations Exclusion Criteria: * No women who are pregnant or nursing * No known hypersensitivity to gemcitabine or nab-paclitaxel * No concurrent herbal or unconventional therapy * No prior therapy with IL-15 or IL-15 analog * No ongoing toxicity from prior anti-cancer treatment that may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must resolve to grade 1 or baseline before administration of the study treatment. * No positive Hep C serology or active Hep B infection * No congestive heart failure \< 6 months * No unstable angina pectoris \< 6 months * No myocardial infarction \< 6 months * No history of ventricular arrhythmias or severe cardiac dysfunction * No history of uncontrollable supraventricular arrhythmias * No New York Heart Association Class \> II congestive heart failure * No marked baseline prolongation of QT/QTc interval * No known autoimmune disease requiring active treatment. Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease * No known prior organ allograft or allogeneic transplantation * No known HIV-positive or AIDS unless patient is on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 (cluster of differentiation 4) counts \>350, with no detectable viral load on quantitative polymerase chain reaction test * No untreated central nervous system metastases, or if treated must be neurologically stable for at least 2 weeks prior to enrollment * No corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) * No psychiatric illness/social situation that would limit compliance * No other illness that in the opinion of the investigator would exclude the subject from participating in the study * No active systemic infection requiring parenteral antibiotic therapy * No anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment start * No disease requiring systemic immunosuppressive therapy * No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 3 years after surgical treatment.